Dyadic International Inc.
| NASDAQ: DYAI |
| Healthcare / Biotechnology / USA |
| 3.57 | -0.0300 | -0.83% | Vol 65.20K | 1Y Perf -60.53% |
| Jul 23rd, 2021 16:00 DELAYED |
| BID | 3.55 | ASK | 3.57 | ||
| Open | 3.60 | Previous Close | 3.60 | ||
| Pre-Market | - | After-Market | - | ||
| - - | - -% |
| Target Price | 8.00 | Analyst Rating | Strong Buy 1.00 | |
| Potential % | 124.09 | Finscreener Ranking | — - | |
| Insiders Trans % 3/6/12 mo. | -/-/- | Value Ranking | — - | |
| Insiders Value % 3/6/12 mo. | -/-/- | Growth Ranking | — - | |
| Insiders Shares Cnt. % 3/6/12 mo. | -/-/- | Income Ranking | — - | |
| Market Cap | 98.37M | Earnings Rating | — | |
| Price Range Ratio 52W % | 6.95 | Earnings Date | 12th Aug 2021 |
Today's Price Range 3.473.61 | 52W Range 3.159.19 | 5 Year PE Ratio Range -19.701.00 |
Summary:
Neutral
| Technical Indicators: | Neutral |
| Moving Averages: | Sell |
| Performance | |||
|---|---|---|---|
| 1 Week | 5.00% | ||
| 1 Month | 1.13% | ||
| 3 Months | -27.44% | ||
| 6 Months | -39.08% | ||
| 1 Year | -60.53% | ||
| 3 Years | 139.28% | ||
| 5 Years | 119.02% | ||
| 10 Years | 123.13% |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | 40.19 | |||
ROE last 12 Months | -4.09 | |||
ROA (5Y Avg) | 17.81 | |||
ROA last 12 Months | -3.96 | |||
ROC (5Y Avg) | 14.78 | |||
ROC last 12 Months | -4.09 | |||
Return on invested Capital Q | -2.51 | |||
Return on invested Capital Y | -6.17 | |||
Assets Turnover | 0.00 | |||
Receivables Turnover | 1.70 |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -8.90 | ||||
| 3.65 | ||||
| 111.23 | ||||
| 52.10 | ||||
| -20.50 | ||||
| -0.24 | ||||
| 3.65 | ||||
| 0.93 | ||||
| 66.45M | ||||
| Forward PE | - | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 33.30 | ||||
| 39.80 | ||||
| - | ||||
| - | ||||
| - | ||||
| Leverage Ratio | 1.00 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 9.90 | ||||
| -560.60 | ||||
| -560.60 | ||||
| -230.60 | ||||
| - |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 819.98K | ||||
| 0.03 | ||||
| -64.69 | ||||
| -54.45 |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q03 2020 | -0.08 | -0.09 | -12.50 |
| Q02 2020 | -0.05 | -0.10 | -100.00 |
| Q01 2020 | -0.02 | -0.08 | -300.00 |
| Q04 2019 | - | -0.07 | - |
| Q03 2019 | -0.07 | -0.06 | 14.29 |
| Q02 2019 | -0.07 | -0.10 | -42.86 |
| Q01 2019 | - | -0.08 | - |
| Q02 2018 | - | -0.06 | - |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| Next Report Date | 12th Aug 2021 |
| Estimated EPS Next Report | -0.09 |
| Estimates Count | 2 |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 65.20K |
| Shares Outstanding | 27.55M |
| Trades Count | 417 |
| Dollar Volume | 1.09M |
| Avg. Volume | 391.74K |
| Avg. Weekly Volume | 135.06K |
| Avg. Monthly Volume | 275.10K |
| Avg. Quarterly Volume | 234.45K |
Dyadic International Inc. (NASDAQ: DYAI) stock closed at 3.57 per share at the end of the most recent trading day (a -0.83% change compared to the prior day closing price) with a volume of 65.20K shares and market capitalization of 98.37M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 7 people. Dyadic International Inc. CEO is Mark A. Emalfarb.
The one-year performance of Dyadic International Inc. stock is -60.53%, while year-to-date (YTD) performance is -33.64%. DYAI stock has a five-year performance of 119.02%. Its 52-week range is between 3.15 and 9.19, which gives DYAI stock a 52-week price range ratio of 6.95%
Dyadic International Inc. currently has a PE ratio of -8.90, a price-to-book (PB) ratio of 3.65, a price-to-sale (PS) ratio of 111.23, a price to cashflow ratio of 52.10, a PEG ratio of 2.32, a ROA of -3.96%, a ROC of -4.09% and a ROE of -4.09%. The company’s profit margin is -%, its EBITDA margin is -560.60%, and its revenue ttm is $819.98 Thousand , which makes it $0.03 revenue per share.
Of the last four earnings reports from Dyadic International Inc., there were 0 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $-0.09 for the next earnings report. Dyadic International Inc.’s next earnings report date is 12th Aug 2021.
The consensus rating of Wall Street analysts for Dyadic International Inc. is Strong Buy (1), with a target price of $8, which is +124.09% compared to the current price. The earnings rating for Dyadic International Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Dyadic International Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Dyadic International Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 14.46, ATR14 : 0.24, CCI20 : 28.29, Chaikin Money Flow : 0.23, MACD : -0.04, Money Flow Index : 42.57, ROC : 5.31, RSI : 50.34, STOCH (14,3) : 77.78, STOCH RSI : 0.81, UO : 58.35, Williams %R : -22.22), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Dyadic International Inc. in the last 12-months were:
Dyadic International Inc.
Dyadic International Inc is a biotechnology company engaged in the discovery, development, manufacturing and selling of enzymes and other proteins for the bioenergy, biochemical, industrial enzyme and biopharmaceutical industries.
CEO: Mark A. Emalfarb
Telephone: +1 561 743-8333
Address: 140 Intracoastal Pointe Drive, Jupiter 33477, FL, US
Number of employees: 7
